Share on linkedin

Ongoing Trials in Europe

Ongoing phase II/III academic trials in Europe
Trial Acronym Trial objective Principal investigator Participating countries
ESOPEC Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus J Hoeppner (GR)  GR
NeoAEGIS To compare neoadjuvant chemotherapy (MAGIC regimen) to neoadjuvant chemoradiotherapy (CROSS regimen) in junctional adenocarcinoma JV Reynolds (IRL) IRL, UK, FR, DEN
ESOSTRATE – PRODIGE 32 To compare systematic surgery versus surveillance in complete morphological responders to chemoradiotherapy in oesophageal cancer L Bedenne – C Mariette (FR) FR
ROMIO To compare hybrid vs totally mini-invasive vs open oesophagectomy in oesophageal cancer J Blazeby (UK) UK
Pre-SANO Correlation between clinical Complete Response and pathological Complete Response after neoadjuvant chemoradiotherapy JJB Van Lanschot (NL) NL
PROTECT To compare 2 neoadjuvant chemoradiotherapy regimen in oesophageal cancer: Carboplatin-Paclitaxel +radiotherapy (CROSS regimen) vs. Folfox + radiotherapy A Adenis – C Mariette (FR) FR
FREGAT Multicenter, Nationwide Prospective data collection of clinical, tumoural, biological, quality of life and human and social sciences data for oesphageal and gastric cancer patients C Mariette (FR) FR
ROBOT Robot vs open transthoracic oesophagectomy for oesophageal cancer R. van Hillegersberg (NL) NL
CONCORDE – PRODIGE 26 Radiotherapy dose escalation in definitive chemoradiotherapy for oesophageal cancer 50.4 Gy vs. 64 Gy G Crehange (FR) FR
ART deco Radiotherapy dose escalation in definitive chemoradiotherapy for oesophageal cancer 50.4 Gy vs. 61.6 Gy M.C.C.M. Hulshof (NL) NL
NEORES II Randomized clinical trial comparing the timing of resective surgery after neoadjuvant chemoradiotherapy in cancer of the esophagus or gastric cardia

ESDE Congress
8-10 February 2023
Leuven, Belgium